Mentions of brand or product names are for identification only and do not constitute endorsement.
Peptide nootropics sit in a strange regulatory limbo. Semax and P21, two synthetic peptides with origins in Russian and American neuroscience, have drawn steady interest from researchers studying cognitive enhancement and neuroprotection. Their mechanisms differ, their histories differ, and the data supporting them differ. The upcoming FDA peptide panel vote could reshape how these compounds are studied, if at all. This article compares what we know about Semax and P21 for focus and anxiety, framed by the research that exists, the gaps that remain, and the regulatory pressure now bearing down on the entire category.
What we'd want to see
A head-to-head trial. Human subjects. Randomized, double-blind, placebo-controlled. Doses matched for effect, endpoints measuring both sustained attention and state anxiety. Maybe something like the 2019 Semax study in stroke patients, but designed for healthy adults under cognitive load. We'd want neuroimaging correlates, BDNF serum levels, and a six-month follow-up. For P21, we'd want replication of its neurogenic claims outside the original lab. We'd want pharmacokinetic profiles that account for intranasal absorption variability. We'd want to know if combining them makes sense, or if one cancels the other. We don't have any of that.
What we have
Semax: the Russian peptide with decades of use
Semax is a heptapeptide, a fragment of adrenocorticotropic hormone (ACTH 4-10) with a Pro-Gly-Pro tripeptide added to the C-terminus. That modification slows enzymatic degradation and appears to alter its receptor profile. Developed in the 1980s at Moscow State University, it has been used clinically in Russia for stroke, ADHD, and cognitive decline. A 2018 review summarized its neuroprotective and nootropic effects, noting increases in BDNF and NGF expression in animal models. Human data is thinner but not absent. A 2019 trial in 110 ischemic stroke patients found Semax improved cognitive recovery scores over placebo, with effects persisting at 30 days. Doses were 6 mg and 12 mg daily, intranasal. For anxiety, the picture is mixed. Some rodent studies show anxiolytic effects, but human data focuses on cognitive outcomes, not mood. Anecdotal reports from nootropic users suggest a subtle, focus-sharpening effect without jitteriness, but that's not evidence.
P21: a CNTF-derived peptide with neurogenic claims
P21 is a small peptide derived from ciliary neurotrophic factor (CNTF). It was developed by a team including Paul Lombroso and others, with a 2005 paper showing it enhanced cognition in rodents. The mechanism is thought to involve inhibition of STEP (striatal-enriched tyrosine phosphatase), which regulates synaptic plasticity. By blocking STEP, P21 may increase BDNF signaling and promote neurogenesis. Most data comes from animal models of Alzheimer's and Down syndrome. A 2014 study found P21 improved spatial memory in aged rats. Doses in the neighbourhood of 0.1-1 mg/kg were used, subcutaneous. Human data is nonexistent. No clinical trials. No pharmacokinetic studies. The compound has been sold as a research chemical, and some nootropic communities report improved focus and memory, but these reports are uncontrolled. Anxiety effects are not well characterized. Some users describe a calm clarity, others note overstimulation at higher doses. The variability could reflect purity issues, dosing inaccuracies, or individual neurochemistry.
Selank, Dihexa, MOTS-c, NAD+: adjacent but distinct
Selank is a synthetic analogue of tuftsin, often compared to Semax for its anxiolytic profile. It has some human research, including a 2008 study showing reduced anxiety in patients with generalized anxiety disorder. Dihexa is a small molecule with extreme potency for hepatocyte growth factor, but human safety data is absent. MOTS-c is a mitochondrial-derived peptide with metabolic effects, studied in 2015 research for insulin sensitivity. NAD+ precursors like nicotinamide riboside have extensive human trials, but they are not peptides. These compounds orbit the same nootropic space, but their mechanisms and risk profiles differ sharply from Semax and P21. The FDA panel vote may not directly address them, but a restrictive precedent could chill research across the board.
What's missing
Comparative data. We have no study pitting Semax against P21. We have no dose-response curves in humans for either. We don't know if intranasal P21 is bioavailable. We don't know if chronic Semax downregulates its targets. We don't know if P21's STEP inhibition has off-target effects on immune function or pain sensitivity. The animal data for P21 is promising but limited to a few labs. The Semax data is broader but mostly in Russian-language journals, with small sample sizes. Long-term safety is unknown for both. The FDA panel will likely note these gaps. If the vote restricts access to research chemicals, the missing data may stay missing. P21's potential for post-COVID cognitive issues remains unexplored in controlled settings. Semax and P21 both show promise for post-stroke recovery, but without trials, that promise stays theoretical.
How to read it
When you see a study claiming cognitive enhancement, check the model. Rodent data doesn't scale linearly. When you see a nootropic vendor citing a Russian trial, find the original paper. Many citations are circular. When you see anecdotal reports, note the confounds: polypharmacy, expectation bias, variable purity. The FDA panel vote is not about banning these peptides outright. It's about reclassifying them in ways that could make research harder or easier. A vote to restrict bulk sales of peptide research chemicals could push labs toward GMP synthesis, raising costs. A vote to create a clearer regulatory pathway could encourage investment. Either way, the current grey market will shift. Researchers relying on third-party suppliers may face supply disruptions. The panel's decision will signal how the agency views the entire category of synthetic peptides with no approved drug status.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.